Nemes Rush Group LLC Sells 5,858 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Nemes Rush Group LLC cut its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 88.8% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 738 shares of the biopharmaceutical company’s stock after selling 5,858 shares during the period. Nemes Rush Group LLC’s holdings in Gilead Sciences were worth $68,000 as of its most recent SEC filing.

Other hedge funds have also bought and sold shares of the company. Southland Equity Partners LLC lifted its position in Gilead Sciences by 3.6% during the fourth quarter. Southland Equity Partners LLC now owns 3,128 shares of the biopharmaceutical company’s stock valued at $289,000 after purchasing an additional 110 shares in the last quarter. Berkshire Bank raised its stake in shares of Gilead Sciences by 3.4% in the fourth quarter. Berkshire Bank now owns 3,398 shares of the biopharmaceutical company’s stock worth $314,000 after buying an additional 111 shares during the period. CFO4Life Group LLC grew its stake in shares of Gilead Sciences by 2.7% during the 4th quarter. CFO4Life Group LLC now owns 4,265 shares of the biopharmaceutical company’s stock valued at $394,000 after acquiring an additional 112 shares during the period. Howe & Rusling Inc. increased its holdings in Gilead Sciences by 2.5% in the 4th quarter. Howe & Rusling Inc. now owns 4,704 shares of the biopharmaceutical company’s stock worth $435,000 after acquiring an additional 115 shares in the last quarter. Finally, GHP Investment Advisors Inc. raised its stake in Gilead Sciences by 1.1% during the 4th quarter. GHP Investment Advisors Inc. now owns 11,354 shares of the biopharmaceutical company’s stock worth $1,049,000 after acquiring an additional 122 shares during the period. 83.67% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of research firms have weighed in on GILD. Morgan Stanley upped their price target on shares of Gilead Sciences from $123.00 to $130.00 and gave the stock an “overweight” rating in a research report on Tuesday, March 11th. Piper Sandler increased their price target on Gilead Sciences from $105.00 to $110.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 12th. Deutsche Bank Aktiengesellschaft upgraded Gilead Sciences from a “hold” rating to a “buy” rating and boosted their price objective for the company from $80.00 to $120.00 in a research report on Tuesday, February 18th. The Goldman Sachs Group increased their target price on Gilead Sciences from $85.00 to $96.00 and gave the stock a “neutral” rating in a research report on Wednesday, February 12th. Finally, JPMorgan Chase & Co. boosted their price target on Gilead Sciences from $120.00 to $130.00 and gave the stock an “overweight” rating in a report on Thursday, March 27th. Eleven analysts have rated the stock with a hold rating, fifteen have given a buy rating and four have assigned a strong buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $105.12.

Insider Transactions at Gilead Sciences

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 142,180 shares of the stock in a transaction on Friday, January 31st. The stock was sold at an average price of $97.22, for a total value of $13,822,739.60. Following the sale, the chief financial officer now owns 129,873 shares in the company, valued at $12,626,253.06. This trade represents a 52.26 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Over the last three months, insiders have sold 302,785 shares of company stock worth $30,503,250. 0.16% of the stock is currently owned by company insiders.

Gilead Sciences Stock Up 0.5 %

Shares of GILD opened at $111.89 on Thursday. The company has a quick ratio of 1.20, a current ratio of 1.50 and a debt-to-equity ratio of 1.24. The business has a fifty day moving average of $106.63 and a 200 day moving average of $95.52. The company has a market cap of $139.32 billion, a PE ratio of 302.41, a P/E/G ratio of 0.71 and a beta of 0.32. Gilead Sciences, Inc. has a 52-week low of $62.07 and a 52-week high of $119.96.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.90 EPS for the quarter, topping analysts’ consensus estimates of $1.67 by $0.23. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%. On average, sell-side analysts expect that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Friday, March 28th. Stockholders of record on Friday, March 14th were paid a dividend of $0.79 per share. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.77. The ex-dividend date was Friday, March 14th. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.82%. Gilead Sciences’s dividend payout ratio is currently 854.05%.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.